Medina-Chávez JH, Colín-Luna JI, Mendoza-Martínez P, Santoyo-Gómez DL, Cruz-Aranda JE

Language: Spanish
References: 22
Page: 332-343
PDF size: 252.96 Kb.

ABSTRACT

The current COVID-19 pandemic, caused by the SARS-CoV-2, has reached Mexico and has brought serious consequences for the general population; a large number of sick people and a considerable number of deaths. Every day, a large number of academic writings are produced that bring case reports and treatment proposals; however, despite these great efforts, from the experience acquired in other countries, the information is still uncertain regarding any treatment that is effective to stop the advance of the pandemic. From these reports we have very valuable data, one of the most relevant is that the most affected people and in greater magnitude in terms of severity are older adults, and even more so if these people have comorbidity with chronic diseases of higher prevalence in our country: hypertension, diabetes mellitus and obesity, conditions that are particularly frequent among older Mexican adults. It is known that this age group has its own changes of aging and atypical forms of manifestation of the disease, as well as in the case of hospitalization, they require finer and constant care for the recovery of health; so, a review and consensus of existing information to offer these recommendations was made for the comprehensive care of older adults with COVID-19.

REFERENCES

1. Zhu N, Zhang D, Wang W, Li X, Yang Bo, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727-733. DOI: 10.1056/ NEJMoa2001017.

2. Organización Mundial de la Salud. COVID-19: Cronología de la actuación de la OMS. 8 de abril de 2020. Consultado en: https://www.who.int/es/news-room/ detail/08-04-2020-who-timeline---covid-19 el día 13 de abril de 2020.

3. Ruan Q, Yang K, Wang W, Jiang L y Song J. Clinical predictors of mortality due to COVID 19 based on analysis of data of 150 patients of Wuhan, China. Intensive Care Medicine (2020). Consultado en: https://doi.org/10.1007/s00134- 020-05991-x el 24 de marzo de 2020.

4. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N Engl J Med April 8, 2020. DOI: 10.1056/ NEJMc2007575.

5. Yan G, Qing C, Zhong G, Yuan T, Shou C, Hong J, et al. The origin, transmission and clinical therapies on coronavirus diseases 2019 (COVID 2019) outbreak – an update on the status. Military Med Res 7, 11 (2020) https://doi. org/10.1186/s40779-020-00240-0.

6. CDC. Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19) March, 7 2020.

7. CDC. Interim Guidance for implementing home care of people not requirirng hospitalization for coronavirus disease 2019 (COVID-19). Febrero 12, 2020. Consultado en: https://www.cdc.gov/coronavirus/2019-ncov/hcp/ guidance-home-care.html.

8. Arrien E, Aguera L, Manzano S. Manejo farmacológico de trastornos psicóticos en personas mayores con tratamiento de la infección por COVID 19: interacciones y recomendaciones terapéuticas. Sociedad Española de Geriatría y Gerontología, Sociedad Española de Neurología, Sociedad Española de Psicogeriatría, Sociedad Española de Medicina Interna. Marzo 2020.

9. Instituto Mexicano del Seguro Social. Curso: Cuidado de personas adultas mayores ante el COVID-19. Dirección de Prestaciones Económicas y Sociales. Disponible en: https:// climss.imss.gob.mx/ accesado el 8 de marzo de 2020.

10. Sociedad Mexicana de Cardiología. Recomendaciones para el paciente con enfermedad cardiovascular ante el COVID-19. 24 de marzo de 2020.

11. GPC. Detección, prevención, diagnóstico y tratamiento del delirium en el adulto mayor hospitalizado. Actualización 2016. Coordinación Técnica de Excelencia Clínica. DPM. IMSS/CENETEC.

12. Rhodes A, Evans L, Alhazzani W, Levy M, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: International guidelines of management of sepsis and septic shock: 2016. Critical Care Med 2017;45;3:486-552. doi: 10.1097/ CCM.0000000000002255

13. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA Published online April 13, 2020. doi:10.1001/jama.2020.6019.

14. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020 Jan 24. DOI: https://doi.org/10.1016/S0140-6736(20)30183-5.

15. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Li Y, Hu B. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. (2020). JAMA Neurol 2020 Apr 10. doi: 10.1001/jamaneurol.2020.1127.

16. Mannan BA, et al. Evidence of the COVID-19 Virus Targeting the CNS: Tissue distribution, host-virus interaction, and proposed neurotropic mechanisms, ACS Chem Neurosci 2020 Apr 1;11(7):995-998. doi: 10.1021/ acschemneuro.0c00122.

17. https://journals.lww.com/neurotodayonline/blog/breakingnews/ pages/post.aspx?PostID=915

18. Fustinoni O. Semiología del sistema nervioso. 14ª ed. Editorial El Ateneo, Julio de 2006.

19. Westover B, et al. Pocket neurology. 2nd ed. Editorial Wolters- Kluwer, 2010.

20. Plum F, Posner J. Diagnóstico del estupor y coma. Editorial Marbán. 1ª edición en español, 2011.

21. Baile WF, Buckman R, Lenzi R, Glober G, Beale EA, Kudelka AP, et al. Six-step protocol for delivering bad news: application to the patient with cancer. Oncologist. 2000;5(4):302- 11. doi: 10.1634/theoncologist.5-4-302.

22. Verkerk MA, de Bree MJ, Mourits MJ. Reflective professionalism: interpreting CanMEDS' “professionalism”. J Med Ethics 2007 Nov;33(11):663-6. doi: 10.1136/ jme.2006.017954.